TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07563829: NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

Sponsor: NextPoint Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 81 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$5,215,056

Rescue Site Savings

+$3,455,760

Unlock Full NCT07563829 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07563829 Rescue Dossier →